{"denoms":[{"counts":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"135"}],"units":"Participants"}],"groups":[{"description":"Patients enrolled to receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.\n\nPatients to receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclophosphamide: Given IV\n\nCyclosporine: Given IV and PO\n\nFludarabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV and PO\n\nTotal-Body Irradiation: Undergo high-dose TBI\n\nUmbilical Cord Blood Transplantation: Undergo UCBT (either single- or double-cord)","id":"BG000","title":"Regimen A: High-dose TBI + Fludarabine + Cyclophosphamide"},{"description":"Patients enrolled to receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.\n\nPatients to receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclophosphamide: Given IV\n\nCyclosporine: Given IV and PO\n\nFludarabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV and PO\n\nTotal-Body Irradiation: Undergo moderate-intensity TBI\n\nUmbilical Cord Blood Transplantation: Undergo UCBT (either single- or double-cord)\n\nThiotepa: Given IV","id":"BG001","title":"Regimen B: Middle-intensity TBI + Fludarabine + Cyclophosphamide + Thiotepa"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"66"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"69"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"45","value":"22"},{"groupId":"BG001","lowerLimit":"1","upperLimit":"63","value":"24.5"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"63","value":"22.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"59"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"76"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"96"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"14"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"85"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"17"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}